TB Alliance is a product development partnership engages in the discovery and development of new tuberculosis (TB) drugs. The company has collaboration agreements with academia, the pharmaceutical and biotechnology industries, public research institutes, and non-governmental organizations namely GlaxoSmithKline, Anacor Pharmaceuticals, Bayer, Novartis and British Medical Research Council etc. TB Alliance currently has three drugs in clinical trials, along with Hundreds of compounds being screened, synthesized, or optimized in discovery and preclinical studies. The TB Alliance pipeline product portfolio includes Moxifloxacin, PA-824, Nitromidazoles, Mycobacterial Gyrase Inhibitors, Riminophenazines, InhA Inhibitors,New Generation Diarylquinoline, Bi-functional Molecules, Phenotypic Screening, Tryptanthrins and LeuRS Inhibitor. The company is Headquartered in Newyork, the US.